Moderna, NIAID Partner on Planned Trial of Coronavirus mRNA Vaccine

Moderna said it has shipped the first batch of its clinic-bound vaccine against novel coronavirus, mRNA-1273, to the NIH’s National Institute of Allergy and Infectious Diseases (NIAID) for use in a planned Phase I study in the U.S. The study, “Safety and Immunogenicity Study of 2019-nCov Vaccine (mRNA-1273) to […]

Click here to view original web page at